×
About 420,254 results

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
https://doi.org/10.1056/NEJMoa1805762
The New England Journal of Medicine; Dimopoulos MA, Dytfeld D et. al.

Nov 7th, 2018 - The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor. Patients with multiple myeloma t...

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or ...
https://doi.org/10.1016/S0140-6736(17)33297-X
Lancet (London, England); Powles T, Durán I et. al.

Dec 22nd, 2017 - Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy in this patient population. We conducted this multicentre, open-label, phase 3 randomised controlled trial (IMvigor211) at 217 academic m...

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
https://doi.org/10.1056/NEJMoa1706450
The New England Journal of Medicine; Robson M, Im SA et. al.

Jun 5th, 2017 - Olaparib is an oral poly(adenosine diphosphate-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation. We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (...

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
https://doi.org/10.1056/NEJMoa1612645
The New England Journal of Medicine; Masuda N, Lee SJ et. al.

May 31st, 2017 - Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracyc...

Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839299
JAMA Inohara T, Xian Y et. al.

Jan 26th, 2018 - Although non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH). To assess the association between preceding oral anticoagulant use (warfarin, NOACs, and no oral anticoagulants [OACs]) and in-hospital mortality among patients with ICH. Retrospective cohort study of 141 31...

Effect of Bag-Mask Ventilation vs Endotracheal Intubation During Cardiopulmonary Resusc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838565
JAMA Jabre P, Penaloza A et. al.

Feb 27th, 2018 - Bag-mask ventilation (BMV) is a less complex technique than endotracheal intubation (ETI) for airway management during the advanced cardiac life support phase of cardiopulmonary resuscitation of patients with out-of-hospital cardiorespiratory arrest. It has been reported as superior in terms of survival. To assess noninferiority of BMV vs ETI for advanced airway management with regard to surviv...

Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervent...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876881
JAMA Berwanger O, Santucci EV et. al.

Mar 11th, 2018 - The effects of loading doses of statins on clinical outcomes in patients with acute coronary syndrome (ACS) and planned invasive management remain uncertain. To determine if periprocedural loading doses of atorvastatin decrease 30-day major adverse cardiovascular events (MACE) in patients with ACS and planned invasive management. Multicenter, double-blind, placebo-controlled, randomized clinica...

Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Ra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578391
Journal of Clinical Oncology : Official Journal of the Am... Chlebowski RT, Aragaki AK et. al.

Jun 27th, 2017 - Purpose Earlier Women's Health Initiative Dietary Modification trial findings suggested that a low-fat eating pattern may reduce breast cancers with greater mortality. Therefore, as a primary outcome-related analysis from a randomized prevention trial, we examined the long-term influence of this intervention on deaths as a result of and after breast cancer during 8.5 years (median) of dietary i...

Empirical Antibiotic Treatment Does Not Improve Outcomes in Catheter-Associated Urinary...
https://doi.org/10.1093/cid/cix680
Clinical Infectious Diseases : an Official Publication Of... Babich T, Zusman O et. al.

Oct 11th, 2017 - Catheter associated urinary tract infection (CAUTI) is the most common healthcare-associated acquired infection. We aimed to describe the short- and long-term survival of patients with CAUTI and the impact of the empirical antibiotic treatment on survival rates. In this prospective observational study we included consecutive adult patients with a chronic indwelling catheter-associated UTI and s...

Public health impact of colonoscopy use on colorectal cancer mortality in Germany and t...
https://doi.org/10.1016/j.gie.2017.04.005
Gastrointestinal Endoscopy; Chen C, Stock C et. al.

Apr 22nd, 2017 - Colonoscopy has been demonstrated to be effective in reducing colorectal cancer (CRC) incidence and mortality and has been widely used for primary CRC screening in Germany and the United States. We performed a population-based analysis to evaluate and compare the public health impact of recent colonoscopy use on CRC deaths among adults aged 55 to 79 years in Germany and the United States from 2...

Outcomes With Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Re...
https://doi.org/10.1016/j.jacc.2017.09.015
Journal of the American College of Cardiology; Sorajja P, Vemulapalli S et. al.

Nov 3rd, 2017 - Post-market surveillance is needed to evaluate the real-world clinical effectiveness and safety of U.S. Food and Drug Administration-approved devices. The authors examined the commercial experience with transcatheter mitral valve repair for the treatment of mitral regurgitation. Data from the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy Registry on pati...

Time to Epinephrine Administration and Survival From Nonshockable Out-of-Hospital Cardi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940513
Circulation Hansen M, Schmicker RH et. al.

Mar 7th, 2018 - Previous studies have demonstrated that earlier epinephrine administration is associated with improved survival from out-of-hospital cardiac arrest (OHCA) with shockable initial rhythms. However, the effect of epinephrine timing on patients with nonshockable initial rhythms is unclear. The objective of this study was to measure the association between time to epinephrine administration and surv...

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
https://doi.org/10.1056/NEJMoa1716948
The New England Journal of Medicine; Socinski MA, Jotte RM et. al.

Jun 4th, 2018 - The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy. We randomly assigned pa...

Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890809
Journal of the American College of Cardiology; Korhonen MJ, Robinson JG et. al.

Sep 24th, 2017 - Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), beta-blockers and statins are recommended after acute myocardial infarction (AMI). Patients may adhere to some, but not all, therapies. The authors investigated the effect of tradeoffs in adherence to ACE inhibitors/ARBs, beta-blockers, and statins on survival among older people after AMI. The authors identif...

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
https://doi.org/10.1056/NEJMoa1713976
The New England Journal of Medicine; Seymour JF, Kipps TJ et. al.

Mar 21st, 2018 - Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive ve...

Effect of Trans-Nasal Evaporative Intra-arrest Cooling on Functional Neurologic Outcome...
https://doi.org/10.1001/jama.2019.4149
JAMA Nordberg P, Taccone FS et. al.

May 7th, 2019 - Therapeutic hypothermia may increase survival with good neurologic outcome after cardiac arrest. Trans-nasal evaporative cooling is a method used to induce cooling, primarily of the brain, during cardiopulmonary resuscitation (ie, intra-arrest). To determine whether prehospital trans-nasal evaporative intra-arrest cooling improves survival with good neurologic outcome compared with cooling init...

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
https://doi.org/10.1056/NEJMoa1612917
The New England Journal of Medicine; Holman RR, Bethel MA et. al.

Sep 14th, 2017 - The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first oc...

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Morta...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605776
JAMA Felker GM, Anstrom KJ et. al.

Aug 22nd, 2017 - The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ("guided therapy") with inconsistent results. To determine whether an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy improves clinical outcomes vs usual car...

Identification of Extremely Premature Infants at Low Risk for Early-Onset Sepsis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654397
Pediatrics Puopolo KM, Mukhopadhyay S et. al.

Oct 6th, 2017 - Premature infants are at high risk of early-onset sepsis (EOS) relative to term infants, and most are administered empirical antibiotics after birth. We aimed to determine if factors evident at birth could be used to identify premature infants at lower risk of EOS. Study infants were born at 22 to 28 weeks' gestation in Neonatal Research Network centers from 2006 to 2014. EOS was defined by iso...

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mo...
https://doi.org/10.1212/WNL.0000000000004508
Neurology Thormann A, Sørensen PS et. al.

Sep 21st, 2017 - To investigate the effect of chronic comorbidity on the time of diagnosis of multiple sclerosis (MS) and on mortality in MS. We conducted a population-based, nationwide cohort study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of diagnosis, we compared individuals with and without chronic comorbidity using multinomial logistic r...